Search Results for “Pfizer” – Page 18 – media

$1.8 billion! Lilly builds factory and expands GLP-1 production

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. Lilly said that the company had completed the $800 million Kinsale factory expansion project to increase the production of its obesity and diabetes drugs Mounjaro and Zepbound. At the same time, the pharmaceutical company will also invest $1 billion to build a factory in Limerick to increase the production of biopharmaceutical raw materials, especially Kisunla, a drug approved by the FDA to treat Alzheimer’s disease two months ago. The production of active pharmaceutical ingredients is expected to begin in 2026. Lilly stated that Limerick’s expansion will add tools for artificial intelligence, automated robots, and machine learning to the website. ...
- Source: drugdu
- 77
- September 16, 2024
A Chinese innovative pharmaceutical company “died”

On September 5, Connect (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company headquartered in the United States, announced its financial results for the six months ended June 30, 2024 and announced plans to large-scale attrition. In addition, as part of Connect’s transformation into a U.S.-focused company, the company plans to significantly reduce the scale of its operations in China. Just a few months ago, Connect was an innovative pharmaceutical company in China. All these changes are rooted in the clinical setbacks of Connect’s core pipeline product, Rademikibart (CBP-201). This is a fully human monoclonal antibody targeting IL-4Rα, which is a common subunit of IL-4Rα and IL-13 receptors. It directly targets Sanofi’s new autoimmune drug Duprilumab. anti. In the CBP-201 clinical data previously announced by Connect, although some connotations of long-term efficacy data were seen, the improvement in the 16-week data was weaker than that of dupilumab; in addition, because it was ...
- Source: drugdu
- 55
- September 13, 2024
The first domestic new drug for alopecia areata is about to be launched

Recently, Hengrui Medicine announced that its application for marketing authorization of emasitinib sulfate tablets (SHR0302 tablets) was accepted by the National Medical Products Administration for the treatment of severe alopecia areata in adults. It is the first domestic JAK inhibitor to be accepted for marketing approval for alopecia areata indications in China. This also means that after Eli Lilly and Pfizer products have been approved in China, Hengrui is likely to become the first domestic company to enter the domestic alopecia areata market. Severe alopecia areata in adults is the fourth indication reported by emasitinib. Last year, it also reported moderate to severe atopic dermatitis, ankylosing spondylitis, and moderate to severe active rheumatoid arthritis in adults and adolescents aged 12 and above. Referring to the progress of Pfizer’s application for listing of Litixitinib Capsules accepted by the National Medical Products Administration in September 2022, included in the ...
- Source: https://mp.weixin.qq.com/
- 82
- September 11, 2024
Zhifei Biological’s 23-valent Pneumococcal Vaccine Price Reduction of Nearly 30%, Another Vaccine Field Will Be Involved in the “Price War”?

September 3, Jilin Province Public Resources Trading Center issued a document that will Zhifei Biological 23-valent pneumococcal polysaccharide vaccine from the original 298/branch down to 209 yuan/branch, down 29.87%. The following day, the Jiangsu Provincial Public Resources Trading Center issued a notice that also reduced the vaccine from 298/branch to 209 yuan/branch. At the end of August last year, Zhifei Biological’s 23-valent pneumococcal polysaccharide vaccine was formally approved for marketing in China for the prevention of infectious diseases caused by pneumococcus bacteria in children aged 2 years and above and adults. According to the half-year report of Zhifei Biological 2024, the approved and issued volume of its 23-valent pneumonia vaccine was 160,000 doses from January to June this year. During the same period, the approved and issued volume of Merck Sharp & Dohme’s 23-valent pneumonia vaccine, for which Zhifei Bio is the agent, amounted to 845,000 units, a year-on-year increase ...
- Source: drugdu
- 82
- September 6, 2024
The victory of tens of billions of dollars, the revelation of the rise of the new vaccine elite

Before the new crown vaccine, Pfizer’s 13-valent pneumococcal vaccine was the world’s “king of vaccines”, with global sales of nearly 6 billion US dollars in 2018, far exceeding the second-place 9-valent HPV vaccine (3.15 billion US dollars). No one wants to miss such a big market. While domestic companies are still rolling up the 13-valent pneumococcal vaccine (PCV13), Vaxcyte is rolling up the price type upgrade. VAX-24 is a vaccine covering 24 virus types, while VAX-31 has rolled up 31 types. Of course, the 13-valent pneumococcal vaccine has brought epoch-making changes to the prevention of pneumonia. However, while the popularity of PCV13 has greatly increased, it has also brought new troubles: the replacement of virus types. Since the introduction of PCV13, the incidence of diseases caused by the serotypes included in the vaccine has decreased. However, there is a phenomenon called serotype replacement, that is, after widespread vaccination, the incremental ...
- Source: drugdu
- 79
- September 6, 2024
Analysis and Prospect of Import and Export Situation of Raw Materials in the First Half of 2024

In the first half of 2024, the total import and export volume of raw materials in China reached 26.52 billion US dollars, a year-on-year increase of 0.6%. Among them, the export value was 21.34 billion US dollars, a slight increase of 0.1% year-on-year; The import volume was 5.18 billion US dollars, a year-on-year increase of 2.8%. 1. Overall Overview and Trend Analysis As the main raw material products in the category of Western medicine import and export products in China, active pharmaceutical ingredients account for 50% of Western medicine foreign trade. From the perspective of exports alone, raw materials account for 80% of the export of Western medicine products. From the import and export situation since 2021, it can be seen that the global demand for active pharmaceutical ingredients has rapidly increased due to the epidemic. In 2022, the foreign trade of active pharmaceutical ingredients reached a historical high, with ...
- Source: drugdu
- 88
- August 31, 2024
Digital Therapeutics Sector See Billing Codes as Key to Breaking Free of Reimbursement Rut

Medicare’s physician fee schedule includes billing codes for digital therapeutics for the first time. Stakeholders say these codes could help turn around reimbursement challenges weighing on the entire digital medicines sector. By Frank VinluanWhen the FDA approves a drug, passing that regulatory bar of safety and efficacy puts it on the path toward likely reimbursement by government and commercial payers. The same has not been true for digital therapeutics. A proposal from the Centers for Medicare and Medicaid Services signals a change in federal thinking about such technologies, which could pave the way for broader coverage of novel digital medicines. For the first time, CMS’s proposed physician fee schedule, a comprehensive annual listing of the fees that Medicare uses to pay doctors, now includes digital therapeutics. The proposal does not cover all digital therapeutics under multiple benefit categories, as the Digital Therapeutics Alliance (DTA) had asked nearly a year ago. ...
- Source: drugdu
- 71
- August 21, 2024
CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come. By Frank VinluanMedicare has unveiled prices for the first 10 drugs selected for its negotiation program, resulting in discounts of as much as 79% off of list prices. Taxpayers will save an estimated $6 billion, the White House said in a Thursday announcement of the new prices. The savings won’t happen right away. New pricing for these products won’t take effect until Jan. 1, 2026 for those with Medicare Part D prescription drug coverage. But these 10 widely used products in therapeutic areas such as diabetes and autoimmune disorders represent the first of many drugs on a path to ...
- Source: drugdu
- 106
- August 19, 2024
Evotec slashes workforce by 400 people in “difficult market”

German life science company Evotec is cutting 400 jobs as the company continues to deal with ‘a more difficult market environment’.” The company’s CEO Christian Wojczewski has announced an accelerated transformation programme for the company, designed to produce cost savings of at least €40m ($44m) next year, he said. One of the reasons cited by Evotec for this challenging environment includes a high fixed cost base for weaker profitability. Nonetheless, the business outlook for FY 2024 involves a slight rise in revenue projections, increasing from €790m to €820m. This is compared to €781m in FY 2023. In May, the company shut down its gene therapy business after its Q1 2024 group revenues were down by 2%. Evotec said its site in Austria will be closed down as part of the restructuring, which affected 40 employees. The company ventured into the gene therapy arena in April 2020, when it teamed up ...
- Source: drugdu
- 96
- August 19, 2024
Q&A with Michael Abrams

By Mike Hollan Abrams discusses how both new pharma and big pharma are reacting to each other and the current market.The last few years have been a rollercoaster ride for the pharma industry. Michael Abrams, managing partner at Numeroff & Associates, spoke with Pharmaceutical Executive about the current state of the industry and what factors are driving M&A and layoffs at the moment. Pharmaceutical Executive: What is driving layoffs in the Pharma sector? Michael Abrams: Despite hopes that the wave of layoffs in 2023 would mark the peak industry pain point, they have continued well into 2024. For big pharma companies, the language used in press releases varies, but the underlying causes are similar: growing pressure on price from government and private sector payers, combined with patent expirations that threaten to cut into revenue. While these are the main real issues, there is, after the surprise passage of the IRA, ...
- Source: drugdu
- 88
- August 17, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.